Che-Yuan Hu

7PUBLICATIONS
14CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 28, 2023
Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.

Che-Yuan Hu, Chi-Feng Hung, Pi-Che Chen

|Apr 13, 2023
Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione Peroxidase 4 and Induction of Ferroptosis.

Che-Yuan Hu, Hung-Tsung Wu, Yan-Shen Shan

|Dec 05, 2022
Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.

Che-Yuan Hu, Bing-Hua Su, Ya-Che Lee

|Nov 17, 2022
The Systemic Immune-Inflammation Index (SII) Increases the Prognostic Significance of Lymphovascular Invasion in Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy.

Hau-Chern Jan, Kuan-Yu Wu, Ta-Yao Tai

|Jan 11, 2022
The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.

Che-Yuan Hu, Kuan-Yu Wu, Tsung-Yen Lin

|Aug 27, 2021
Low Preoperative Mean Platelet Volume/Platelet Count Ratio Indicates Worse Prognosis in Non-Metastatic Renal Cell Carcinoma.

Yu-Chiao Lin, Hau-Chern Jan, Horng-Yih Ou

Pageof 2

Frequent Collaborators

3 joint publications

Chao-Liang Wu

2 joint publications

Hau-Chern Jan

2 joint publications

Horng-Yih Ou

1 joint publications

Kun-Che Lin